Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
7 undervalued US stocks that crushed earnings
stocks
Undervalued ASX share hitting on all cylinders
stocks
Investor Playbook: Can your portfolio handle what’s next?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,187.20 | 17.30 | -0.19% |
| CAC 40 | 8,368.91 | 7.55 | 0.09% |
| DAX 40 | 26,749.95 | 21.93 | -0.08% |
| Dow JONES (US) | 52,347.55 | 50.46 | 0.10% |
| FTSE 100 | 10,902.56 | 39.47 | 0.36% |
| HKSE | 23,835.44 | 197.84 | 0.84% |
| NASDAQ | 25,136.27 | 229.82 | -0.91% |
| Nikkei 225 | 60,042.51 | 1,099.84 | -1.80% |
| NZX 50 Index | 14,274.92 | 101.24 | 0.71% |
| S&P 500 | 7,561.67 | 30.73 | -0.40% |
| S&P/ASX 200 | 9,066.10 | 16.10 | -0.18% |
| SSE Composite Index | 3,620.00 | 14.35 | -0.39% |